Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.40)
# 321
Out of 5,154 analysts
240
Total ratings
44.24%
Success rate
26.25%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $14.27 | -36.93% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $61.18 | +104.32% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.99 | +137.80% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.34 | +1.12% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $21.87 | +119.48% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $8.17 | +193.76% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $6.85 | +177.37% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.98 | +167.26% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $28.87 | +31.62% | 9 | Nov 5, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $53.87 | +16.95% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $21.25 | +394.12% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $62.82 | +87.84% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $57.47 | +28.76% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $6.75 | +137.04% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $27.90 | +7.53% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $16.71 | +384.74% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.57 | +53.17% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $39.68 | +209.98% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.76 | +2,293.62% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.39 | +1,676.20% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $15.39 | +62.44% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $29.43 | +127.66% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.22 | +302.84% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.72 | +194.12% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.23 | +794.31% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.85 | +271.13% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.72 | +1,843.36% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.11 | +1,071.17% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.20 | +1,650.00% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.85 | +224.32% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.41 | +4,730.92% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $6.41 | +258.81% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.90 | +100,312.81% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $28.91 | +1,283.60% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.61 | +3,156.70% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.42 | +2,703.74% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.88 | +9,474.47% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.61 | +583.23% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.38 | +4,247.83% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.77 | +11,623.33% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.66 | +381,718.18% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $6.81 | +44,540.23% | 1 | Jan 9, 2020 |
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $14.27
Upside: -36.93%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $61.18
Upside: +104.32%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.99
Upside: +137.80%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.34
Upside: +1.12%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $21.87
Upside: +119.48%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $8.17
Upside: +193.76%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $6.85
Upside: +177.37%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.98
Upside: +167.26%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $28.87
Upside: +31.62%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $53.87
Upside: +16.95%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $21.25
Upside: +394.12%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $62.82
Upside: +87.84%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $57.47
Upside: +28.76%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $6.75
Upside: +137.04%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $27.90
Upside: +7.53%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $16.71
Upside: +384.74%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.57
Upside: +53.17%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $39.68
Upside: +209.98%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.76
Upside: +2,293.62%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.39
Upside: +1,676.20%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.39
Upside: +62.44%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $29.43
Upside: +127.66%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.22
Upside: +302.84%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.72
Upside: +194.12%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.23
Upside: +794.31%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.85
Upside: +271.13%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.72
Upside: +1,843.36%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.11
Upside: +1,071.17%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.20
Upside: +1,650.00%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.85
Upside: +224.32%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.41
Upside: +4,730.92%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $6.41
Upside: +258.81%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.90
Upside: +100,312.81%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $28.91
Upside: +1,283.60%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.61
Upside: +3,156.70%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.42
Upside: +2,703.74%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.88
Upside: +9,474.47%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.61
Upside: +583.23%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.38
Upside: +4,247.83%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.77
Upside: +11,623.33%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.66
Upside: +381,718.18%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $6.81
Upside: +44,540.23%